675 related articles for article (PubMed ID: 26086566)
1. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.
Karlsen MA; Høgdall EV; Christensen IJ; Borgfeldt C; Kalapotharakos G; Zdrazilova-Dubska L; Chovanec J; Lok CA; Stiekema A; Mutz-Dehbalaie I; Rosenthal AN; Moore EK; Schodin BA; Sumpaico WW; Sundfeldt K; Kristjansdottir B; Zapardiel I; Høgdall CK
Gynecol Oncol; 2015 Sep; 138(3):640-6. PubMed ID: 26086566
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
3. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
[TBL] [Abstract][Full Text] [Related]
4. Copenhagen Index versus ROMA in preoperative ovarian malignancy risk stratification: Result from the first Vietnamese prospective cohort study.
Tran DT; Vo VK; Le MT; Chuang L; Nguyen VQH
Gynecol Oncol; 2021 Jul; 162(1):113-119. PubMed ID: 33994145
[TBL] [Abstract][Full Text] [Related]
5. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
6. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
Lycke M; Kristjansdottir B; Sundfeldt K
Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
[TBL] [Abstract][Full Text] [Related]
7. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
[TBL] [Abstract][Full Text] [Related]
8. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
Wang Z; Tao X; Ying C
Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130
[TBL] [Abstract][Full Text] [Related]
9. HE4 and ROMA index in Czech postmenopausal women.
Novotny Z; Presl J; Kucera R; Topolcan O; Vrzalova J; Fuchsova R; Betincova L; Rokyta Z
Anticancer Res; 2012 Sep; 32(9):4137-40. PubMed ID: 22993374
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of human epididymis protein 4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women.
Nikolova T; Zivadinovic R; Evtimovska N; Klisarovska V; Stanojevic M; Georgievska J; Nikolova N
J Obstet Gynaecol Res; 2017 Dec; 43(12):1870-1879. PubMed ID: 29027715
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].
Shipeng G; Yongning C; Yadi Z; Chanyuan LI; Qifan J
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec; 39(12):1393-1401. PubMed ID: 31907150
[TBL] [Abstract][Full Text] [Related]
12. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
[TBL] [Abstract][Full Text] [Related]
13. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
[TBL] [Abstract][Full Text] [Related]
14. Approaches to the detection of ovarian cancer.
Høgdall E
Scand J Clin Lab Invest Suppl; 2016; 245():S49-53. PubMed ID: 27435369
[TBL] [Abstract][Full Text] [Related]
15. Modification of cutoff values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for ovarian cancer detection in Jakarta, Indonesia.
Winarto H; Laihad BJ; Nuranna L
Asian Pac J Cancer Prev; 2014; 15(5):1949-53. PubMed ID: 24716917
[TBL] [Abstract][Full Text] [Related]
16. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
[TBL] [Abstract][Full Text] [Related]
17. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
[TBL] [Abstract][Full Text] [Related]
18. [Ovarian tumor markers of presumed benign ovarian tumors].
Lahlou N; Brun JL
J Gynecol Obstet Biol Reprod (Paris); 2013 Dec; 42(8):752-9. PubMed ID: 24210243
[TBL] [Abstract][Full Text] [Related]
19. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.
Terlikowska KM; Dobrzycka B; Witkowska AM; Mackowiak-Matejczyk B; Sledziewski TK; Kinalski M; Terlikowski SJ
J Ovarian Res; 2016 Jul; 9(1):43. PubMed ID: 27436085
[TBL] [Abstract][Full Text] [Related]
20. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS
J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]